Athena Athena

X
[{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tizona Initiates Clinical Development of TTX-080 in Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$1,550.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tizona Initiates Phase 1b Expansion Study of TTX-080 in Advanced Refractory or Resistant Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by Tizona Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The Phase 1b expansion study follows the Phase 1a study, an open label, multicenter, dose escalation clinical trial designed to assess the safety and tolerability of TTX-080 as monotherapy.

            Lead Product(s): TTX-080,Pembrolizumab

            Therapeutic Area: Oncology Product Name: TTX-080

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 14, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Gilead can exercise its option to acquire the remainder of Tizona following the readout of a Phase 1b study of Tizona’s investigational antibody, TTX-080, or earlier if Gilead decides to do so.

            Lead Product(s): TTX-080

            Therapeutic Area: Oncology Product Name: TTX-080

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Gilead Sciences

            Deal Size: $1,550.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition July 21, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            TTX-080 prevents the suppression of both innate and adaptive immune activity and has the potential to enhance anti-tumor responses. Tizona plans to evaluate TTX-080 as both a monotherapy and in combination therapy in advanced cancers in a Phase 1 clinical trial.

            Lead Product(s): TTX-080

            Therapeutic Area: Oncology Product Name: TTX-080

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 25, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY